Literature DB >> 1531786

Echocardiographic left ventricular hypertrophy: clinical characteristics. The Framingham Heart Study.

D Levy1, J M Murabito, K M Anderson, J C Christiansen, W P Castelli.   

Abstract

Recent data suggest that echocardiographic left ventricular (LV) hypertrophy is associated with increased cardiovascular morbidity and mortality. Based upon application of sex-specific echocardiographic criteria for LV hypertrophy, the clinical characteristics of 863 subjects with and 4097 subjects without LV hypertrophy are examined. Subjects with LV hypertrophy are older, more obese, have higher blood pressure, and are more likely to have pre-existing coronary artery disease. In addition subjects with LV hypertrophy have a higher prevalence of reduced echocardiographic fractional shortening. We conclude that subjects with echocardiographic LV hypertrophy are at high risk for cardiovascular disease complications by virtue of their clinical profile. Additional investigation of the benefits of therapeutic interventions directed toward the prevention or regression of LV hypertrophy is warranted.

Entities:  

Mesh:

Year:  1992        PMID: 1531786     DOI: 10.3109/10641969209036173

Source DB:  PubMed          Journal:  Clin Exp Hypertens A        ISSN: 0730-0077


  8 in total

1.  Serum Amyloid P-Component Prevents Cardiac Remodeling in Hypertensive Heart Disease.

Authors:  Stephen J Horgan; Chris J Watson; Nadia Glezeva; Pat Collier; Roisin Neary; Isaac J Tea; Niamh Corrigan; Mark Ledwidge; Ken McDonald; John A Baugh
Journal:  J Cardiovasc Transl Res       Date:  2015-11-17       Impact factor: 4.132

2.  Association of cardiovascular disease risk factors with left ventricular mass, biventricular function, and the presence of silent myocardial infarction on cardiac MRI in an asymptomatic population.

Authors:  Eliel Nham; Sung Mok Kim; Sang-Chol Lee; Sung-A Chang; Jidong Sung; Soo Jin Cho; Shin Yi Jang; Yeon Hyeon Choe
Journal:  Int J Cardiovasc Imaging       Date:  2016-05-21       Impact factor: 2.357

3.  The cardiac MRI substudy to ongoing telmisartan alone and in combination with ramipril global endpoint trial/telmisartan randomized assessment study in ACE-intolerant subjects with cardiovascular disease: analysis protocol and baseline characteristics.

Authors:  Brett R Cowan; Alistair A Young; Craig Anderson; Robert N Doughty; Rungroj Krittayaphong; Eva Lonn; Thomas H Marwick; Chris M Reid; John E Sanderson; Roland E Schmieder; Koon Teo; Angela K Wadham; Stephen G Worthley; Cheuk-Man Yu; Salim Yusuf; Garry L Jennings
Journal:  Clin Res Cardiol       Date:  2009-04-04       Impact factor: 5.460

Review 4.  Differential Role of Leptin and Adiponectin in Cardiovascular System.

Authors:  C M Ghantous; Z Azrak; S Hanache; W Abou-Kheir; A Zeidan
Journal:  Int J Endocrinol       Date:  2015-05-03       Impact factor: 3.257

5.  Bilirubin Level is Associated with Left Ventricular Hypertrophy Independent of Blood Pressure in Previously Untreated Hypertensive Patients.

Authors:  Teslime Ayaz; Murtaza Emre Durakoğlugil; Sinan Altan Kocaman; Tuğba Durakoğlugil; Turan Erdoğan; Osman Zikrullah Sahin; Serap Baydur Sahin; Yüksel Ciçek; Omer Satiroğlu
Journal:  Korean Circ J       Date:  2014-09-25       Impact factor: 3.243

6.  Impact of regional left ventricular function on outcome for patients with AL amyloidosis.

Authors:  Dan Liu; Kai Hu; Markus Niemann; Sebastian Herrmann; Maja Cikes; Stefan Störk; Meinrad Beer; Philipp Daniel Gaudron; Caroline Morbach; Stefan Knop; Eva Geissinger; Georg Ertl; Bart Bijnens; Frank Weidemann
Journal:  PLoS One       Date:  2013-03-08       Impact factor: 3.240

7.  Relationship between Serum Bilirubin and Left Ventricular Hypertrophy in Patients with Essential Hypertension.

Authors:  Tao Zhou; Xiaofang Chen; Zhanzhan Li; Lezhi Li
Journal:  PLoS One       Date:  2015-04-27       Impact factor: 3.240

Review 8.  Chronic Heart Failure and Comorbid Renal Dysfunction - A Focus on Type 2 Cardiorenal Syndrome.

Authors:  Jois Preeti; Mebazaa Alexandre; Iyngkaran Pupalan; Thomas C Merlin; Ronco Claudio
Journal:  Curr Cardiol Rev       Date:  2016
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.